Advances in bevacizumab combined with XELOX regimen in the treament of metastatic colorectal cancer
10.11904/j.issn.1002-3070.2015.02.014
- VernacularTitle:贝伐单抗联合 XELOX 方案治疗转移性结直肠癌的研究进展
- Author:
Jie CHEN
;
Encun HOU
- Publication Type:Journal Article
- Keywords:
Colorectal cancer;
Bevacizumab;
XELOX;
Oxaliplatin;
Capecitabine
- From:
Practical Oncology Journal
2015;(2):157-161
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is a common malignant tumor in digestive system ,with an increasing inci-dence rate and case fatality rate all over the world in recent decades .At present,chemotherapy still plays a very important role in the treatment of advanced colorectal cancer .Targeted therapy brings new hope to patients ,and new chemotherapy drugs and targeted drugs have been widely used in clinics .Patient′s life quality has been great-ly improved,survival time has been significantly prolonged ,the combination of chemotherapy and targeted therapy has also become a hot research area in the treatment of metastatic colorectal cancer .XELOX ( capecitabine plus oxaliplatin)as a first-line chemotherapy regimen in treating metastatic colorectal cancer (mCRC)can obtain good therapeutic effect ,the side effects of XELOX are light and well tolerated;Bevacizumab ,as a new type of targeted anti-tumor drugs ,shows a good effect in inhibiting tumor growth and reducing its hematogenous spread risk .Bev-acizumab in combination with XELOX regimen for treating mCRC has been widely investigated and reported .This review gives a brief summary on the efficacy and safety of the combined administration of Bevacizumab and XE -LOX.
